Estimating the mean and variance from the median, range, and the size of a sample

Comparative effectiveness of pharmacological and non-pharmacological interventions for dyspnea management in advanced cancer: A systematic review and network meta-analysis

Objective

This study aimed to evaluate and rank the effectiveness of pharmacological and non-pharmacological interventions for managing dyspnea severity, anxiety, exercise capacity, and health-related quality of life (HRQoL) in patients with advanced cancer.

Methods

A comprehensive search of PUBMED, HINARI, CENTRAL, and ResearchGate was conducted to identify randomized controlled trials (RCTs) published up to March 2024. Network meta-analysis was performed to compare interventions, calculating mean differences (MD) and standardized mean differences (SMD) with 95% confidence intervals (CI). P-scores were used to rank the interventions. Risk of bias was assessed using the Cochrane tool, and the quality of evidence (QOE) was evaluated using the GRADE framework.

Results

A total of 42 RCTs, encompassing 3,832 patients, were included in the analysis. Among the evaluated interventions, high-flow nasal cannula (HFNC) demonstrated the most significant improvement in dyspnea relief (SMD = -1.91; 95% CI: -3.32 to -0.49; QOE: moderate), followed by acupressure/reflexology (SMD = -1.04; 95% CI: -2.02 to -0.06; QOE: very low). Activity rehabilitation was the only intervention that significantly reduced anxiety compared to the control group (SMD = -0.64; 95% CI: -0.97 to -0.32; QOE: very low). While all interventions showed trends of improving exercise capacity, none reached statistical significance. Notably, acupressure/reflexology significantly enhanced HRQoL (SMD = 1.55; 95% CI: 0.22 to 2.88; QOE: moderate).

Conclusions

Non-pharmacological interventions, particularly HFNC and acupressure/reflexology, were more effective than pharmacological approaches in improving dyspnea relief and HRQoL. However, the low quality of evidence underscores the need for high-quality, large-scale trials to confirm these findings and refine treatment strategies for dyspnea management in advanced cancer patients.

Systematic review registration

PROSPERO CRD42023479041.

Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States

BACKGROUND

Glofitamab is a T-cell engaging bispecific monoclonal antibody that was granted accelerated approval from the United States Food and Drug Administration for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after ≥2 lines of systemic therapy (3L+).

METHODS

A budget impact model was developed for a hypothetical blended commercial/Medicare health plan with 1,000,000 members. Comparators were axicabtagene ciloleucel (Axi-cel), lisocabtagene maraleucel (Liso-cel), tisagenlecleucel (Tisa-cel), loncastuximab tesirine, polatuzumab vedotin + bendamustine + rituximab, rituximab + gemcitabine + oxaliplatin, tafasitamab + lenalidomide, and epcoritamab (Epcor). Total costs included those for drugs, wastage, administration, grade ≥3 adverse reactions, and all-grade cytokine release syndrome) and routine care. Market shares were based on internal projections and expert opinions. Total and per-member per-month (PMPM) net budget impacts over 3 years were calculated.

RESULTS

Approximately nine patients were projected to be eligible for 3L + DLBCL treatment in a health plan of 1,000,000 members. The introduction of glofitamab as a treatment option resulted in estimated total and PMPM cost savings of $728,697 and -$0.0202, respectively, over 3 years. Costs were reduced across all cost categories but particularly in drug costs. Among the newer therapies, total 3-year cost per treated patient was lowest for glofitamab: $226,658 versus Tisa-cel = $564,113; Axi-cel = $540,002; Liso-cel = $516,272; and Epcor = $335,293. Across all sensitivity analyses, the inclusion of glofitamab had minimal PMPM budget impact, ranging from -$0.0256 to -$0.0108.

CONCLUSIONS

With the lowest 3-year total cost per treated patient among the newer therapies, glofitamab being an available option in the 3L + DLBCL market is estimated to save a hypothetical 1,000,000-member health plan $728,697 in cumulative total costs and $0.0202 in PMPM costs over 3 years.

Extracorporeal membrane oxygenation in pregnancy and the post-partum period: a systematic review and meta-analysis

OBJECTIVE

There is an increase in the application data of Extracorporeal Membrane Oxygenation (ECMO) in perinatal women, particularly since the outbreak of coronavirus disease 2019. Therefore, we reviewed publications on the use of ECMO in pregnant and postpartum women and analyzed the maternal and fetal outcomes, updated the progress of ECMO in perinatal women.

METHODS

We conducted a systematic literature search across PubMed, EMBASE, Cochrane Library, and the International Clinical Trials Registry (ICTRP), yielding 30 eligible clinical studies that investigated the application of ECMO during pregnancy. A comprehensive data extraction process was implemented to retrieve information from these selected studies. A single rate analysis on material survival, material harmonic compilations, and fetus survival were performed by R software.

RESULTS

Of the 1460 women included, our primary outcome was maternal survival: 74.4% (95% confidence interval [CI]: 67.8%-81.1%). Among them, the survival rate of VV ECMO patients was 83.6% (95% confidence interval [CI]: 76.4%-90.8%); the survival rate of VA ECMO patients was 62.8% (95% confidence interval [CI]: 48.7%-76.8%). The secondary outcomes were maternal hemorrhagic complications: 34.8% (95% [CI]: 24.1%-45.5%), and fetal survival: 73.2% (95% [CI]: 62.0%-84.4%).

CONCLUSIONS

Our analysis revealed that the outcomes of ECMO (both type) use in pregnant patients may be comparable or superior to those observed in non-pregnant cohorts. Moreover, patients treated with VV ECMO exhibited a significantly higher survival rate compared to those on VA ECMO.

DETAILS OF REGISTRATION

The protocol for this systematic review was registered on INPLASY (2022110036) in 11 November 2022.

Effect of Chromium Supplementation on Serum Levels of Inflammatory Mediators: An Updated Systematic Review and Meta-analysis on Randomized Clinical Trials

Chromium has been recognized for its beneficial effects on inflammation reduction; therefore, we conducted a systematic review and meta-analysis to find the effect of chromium supplementation on serum levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) in subjects aged 18 years and older. Related articles were identified by searching databases such as the Cochrane Library, ClinicalTrials.gov, ISI Web of Science, Scopus, and PubMed up until Agust 2024. We computed the mean differences (MD) along with their standard deviations (SDs) to carry out the meta-analysis. Statistical heterogeneity of the intervention effects was assessed using I-squared statistics and Cochran's Q test. In total, twelve and eleven studies were included in the present systematic review and meta-analysis, respectively. The pooled results indicated that the differences in serum levels of CRP and TNF-α between chromium group and the comparison group were statistically significant (CRP: weighted mean difference (WMD) = -0.58 mg/L; 95% confidence interval (CI) = -0.95, -0.22 mg/L; P = 0.002; TNF-α: WMD = -1.22 pg/ml; 95% CI = -1.91, -0.53 pg/ml; p = 0.001). In contrast, chromium supplementation resulted in a non-significant decrease in serum levels of IL-6 (WMD = -0.63 pg/ml; 95% CI: -1.67, 0.4 pg/ml; P < 0.001). Our study supports the beneficial effect of chromium supplementation on serum concentration of CRP and TNF-α, but our results showed that chromium supplementation non-significantly reduced the serum levels of IL-6. However, it seems that chromium formulation, participants' BMI, sample size, and geographical region are strong variables that predict the effect of chromium supplementation on inflammatory mediators.

Factors associated with thrombosis in Behçet Syndrome: A systematic review and meta-analysis

OBJECTIVES

Thrombosis is an important component of vascular involvement in Behçet syndrome (BS). Inflammation seems to be the main cause, while the contribution of factors associated with thrombosis is debated.

METHODS

We searched PubMed and EMBASE for studies that assessed factors associated with thrombosis in patients with BS. We separately analyzed studies that compared BS patients with thrombosis to BS patients without thrombosis and studies that compared BS patients with thrombosis to non-BS patients with thrombosis. The pooled odds ratios with 95%CI were calculated for binary outcomes and standardized mean differences were calculated for continuous outcomes.

RESULTS

A total of 87 factors were compared between BS patients with thrombosis and BS patients without thrombosis in 101 studies. Having a Factor V Leiden mutation increased the risk of thrombosis 2.58 times (95% CI 1.76 to 3.78) among patients with BS. Homocysteine levels and factor VIII levels were also significantly higher among BS patients with thrombosis. There were only 6 studies including 14 factors that compared BS patients with thrombosis to non-BS patients with thrombosis. The frequencies of JAK-2 mutation, activated protein C resistance, levels of tissue plasminogen activator (tPA) and activity of tPA were significantly higher among non-BS patients with thrombosis.

CONCLUSION

Prothrombotic factors do not seem to be the main driver of thrombosis in BS, but may pose an additional risk when present. Screening BS patients with thrombosis for common prothrombotic factors may be reasonable, especially in patients with unusual clinical and demographic features for vascular involvement of BS.

Effect of the Mediterranean Diet Supplemented With Olive Oil Versus the Low-Fat Diet on Serum Inflammatory and Endothelial Indexes Among Adults: A Systematic Review and Meta-analysis of Clinical Controlled Trials

CONTEXT

Inflammation and endothelial dysfunction are important risk factors for chronic diseases, including cardiovascular diseases and related mortality.

OBJECTIVE

This systematic review and meta-analysis aimed to assess the effects of 2 popular dietary patterns-a Mediterranean (MED) diet supplemented with olive oil and a low-fat diet (LFD)-on factors related to inflammation and endothelial function in adults.

DATA SOURCES AND DATA EXTRACTION

The following online databases were searched for related studies published until August 7, 2024: PubMed/Medline, Scopus, Clarivate Analytics Web of Science, Cochrane Central Register of Controlled Trials, and Google Scholar. Two independent researchers selected the studies based on the eligibility criteria.

DATA ANALYSIS

The effect sizes were expressed as Hedges' g with 95% CIs. A total of 16 eligible trials with 20 effect sizes were included in the analyses. This meta-analysis revealed that the MED diet supplemented with olive oil significantly improved all of the indicators of the study compared with the LFD, except in the case of E-selectin, in which a low and nonsignificant decrease was reported.

CONCLUSION

Available evidence suggests that a MED diet supplemented with olive oil compared with the LFD significantly improves inflammation and serum endothelial function in adults.

SYSTEMATIC REVIEW REGISTRATION

PROSPERO registration no. CRD42023485718.

Effect of Total and Partial Meal Replacements on Factors Related to Glucose Metabolism: A Systematic Review and Meta-analysis of Randomized Controlled Trials

CONTEXT

Although some evidence shows the beneficial effects of meal replacements (MRs) on glucose metabolism as one of the main factors of diabetes, there are still no comprehensive findings in this field.

OBJECTIVE

We investigated the effects of total and partial MRs on fasting blood sugar (FBS), insulin, glycated hemoglobin (HbA1c), and homeostatic model assessment for insulin resistance (HOMA-IR) in this comprehensive study and meta-analysis.

DATA SOURCES

To find pertinent randomized controlled trials (RCTs) up to March 2024, databases including PubMed/Medline, Web of Science, Scopus, and Embase were searched.

DATA EXTRACTION

This study included all RCTs investigating the effects of MRs on factors related to glucose metabolism. The pooled weighted mean difference (WMD) and 95% CIs were computed using the random-effects model.

DATA ANALYSIS

The findings from 52 studies indicated significant reductions in FBS (WMD: -3.10 mg/dL; 95% CI: -4.99, -1.20; P < .001), insulin (WMD: -1.79 μU/mL; 95% CI: -3.51, -0.08; P = .40), HOMA-IR (WMD: -0.86; 95% CI: -1.68, -0.04; P = .040), and HbA1c (WMD: -0.24%; 95% CI: -0.35%, -0.13%; P < .001) levels following MR consumption compared with the control group. The findings obtained from the subgroup analysis showed that MRs cause a greater decrease in FBS, insulin, and HOMA-IR in the >50-years age group compared with those aged ≤50 years and also during interventions ≤24 weeks compared with >24 weeks.

CONCLUSION

In conclusion, it appears that MRs, along with other lifestyle factors, can lead to significant improvements in glucose metabolism.

Efficacy of neuromodulation and rehabilitation approaches on pain relief in patients with spinal cord injury: a systematic review and meta-analysis

INTRODUCTION

Spinal cord injury (SCI) is a debilitating neurological condition that causes physical dependency, psychological distress, and financial burden. Pain is a common consequence of SCI, significantly impacting quality of life. Effective pain management in SCI is challenging and requires multifaceted approaches. Among rehabilitation methods, non-invasive brain stimulation techniques such as repetitive transcranial magnetic stimulation (rTMS), theta burst stimulation (TBS), transcranial direct current stimulation (tDCS), transcutaneous electrical nerve stimulation (TENS), and virtual reality (VR) have been explored. This study aims to evaluate the efficacy of rehabilitation and non-invasive brain stimulation techniques on pain relief in SCI patients.

METHODS

A systematic review of the literature was conducted using PubMed, Scopus, and ScienceDirect with the formula ("spinal cord injury") AND ("pain"). Risk of bias was assessed using the Cochrane Risk of Bias Tool.

RESULTS

Sixteen studies involving 319 patients were included. Patients in the control groups received: rTMS in seven trials, tDCS in seven trials, TBS in one trial, and TENS combined with VR in one trial. The trials analyzed were of poor methodological quality, characterized by small sample sizes, weak power analyses, varying clinical scores, and non-comparable follow-up periods. No major complications or serious adverse events were reported.

CONCLUSION

Results were inconsistent, with no solid evidence supporting the superiority of rehabilitation techniques over comparator treatments. However, the favorable safety profile and positive outcomes in some measures suggest potential benefits for pain management and quality of life. Further studies are necessary to better understand SCI-related pain and optimize treatment strategies.

Paravertebral block is not superior to the interpectoral and pectoserratus plane block for patients undergoing breast surgery: An updated meta-analysis of randomised controlled trials with meta-regression and trial sequential analysis

BACKGROUND

Breast surgery is frequently associated with significant acute postoperative pain, necessitating effective pain management strategies. Both thoracic paravertebral block (PVB) and interpectoral plane and pectoserratus plane (IP+PS) blocks have been used to relieve pain after breast surgery.

OBJECTIVE

In this systematic review and meta-analysis with trial sequential analysis, we aimed to identify the optimal analgesic technique for achieving effective pain relief in breast surgery. The primary outcome of this study was postoperative opioid consumption expressed as morphine milligram equivalent (MME) at 24 h. Secondary outcomes included resting and movement pain scores at 0, 6, 12 and 24 h, postoperative nausea and vomiting (PONV), and rescue analgesic requirements within the first 24 h.

DESIGN

A meta-analysis of randomised controlled trials (RCTs) with meta-regression and trial sequential analysis (TSA).

DATA SEARCH

We systematically searched Pubmed, Scopus, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Google Scholar, Medline (from inception to until 1 October 2024).

ELIGIBILITY CRITERIA

RCTs that include patients undergoing breast surgery with PVB or IP+PS block, with no language restriction.

RESULTS

Eighteen RCTs with 924 patients were included. No significant difference in MME consumption at 24 h was observed between the two techniques; mean difference (MD) -1.94 (95% confidence interval (CI) -4.27 to 0.38, P = 0.101). Subgroup analyses revealed a minor advantage for IP+PS in patients without axillary involvement; MD -2.42 (95% CI -3.56 to -1.29, P  < 0.001), though below the threshold of clinical significance. Secondary outcomes, including pain scores, PONV incidence and rescue analgesic requirements were comparable. Trial sequential analysis (TSA) confirmed sufficient sample size, suggesting further studies may not alter conclusions.

CONCLUSION

PVB and IP+PS blocks offer comparable analgesic efficacy and opioid-sparing effects after breast surgery, with no meaningful differences in 24-h MME consumption, pain scores, or PONV incidence.

Tranexamic acid use in rotator cuff repair: A systematic review of perioperative outcomes

Background

Tranexamic acid (TXA) use has become the gold standard in total joint arthroplasty to limit intraoperative blood loss and transfusion rates. More recently, the indications for TXA have expanded to knee and shoulder arthroscopy with promising early results. However, the effectiveness of TXA during arthroscopic rotator cuff repair (RCR) is unclear. Therefore, the purpose of this study was to investigate perioperative outcomes following the use of TXA during RCR.

Methods

A systematic review was performed via the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines using PubMed, MEDLINE, Embase, and Cochrane databases in November 2024. Studies were assessed for quality of visual clarity, operative time, mean arterial pressure (MAP), volume of arthroscopy irrigation used, arthroscopic pump pressure, and clinical outcomes.

Results

A total of 12 clinical trials involving 999 patients were included. 9 studies reported on visual clarity and 6 of these reported improvements in visual clarity with TXA administration. Four studies reported improvements in postoperative pain, however outcomes varied greatly depending on when follow-up assessment occurred. A majority of studies did not report differences in operative time, irrigation volume, or postoperative swelling. There were no venous thromboembolism events reported in the included studies.

Conclusion

TXA dosing during RCR surgery may improve visual clarity, however its effect on other perioperative outcomes remains unclear.

Level of evidence

Level I.

Swallowed topical steroid maintenance therapy for eosinophilic esophagitis: A systematic review and meta-analysis

BACKGROUND

Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder presenting as symptoms of dysphagia, esophageal food impaction, chest pain, and heartburn. After an initial trial of proton pump inhibitor (PPI) therapy, swallowed topical corticosteroids (STC) are effective as induction therapy for EoE. However, outcome data for STC as a maintenance strategy is limited.

AIM

To systematically evaluate the long-term outcomes and safety of maintenance treatment with STC.

METHODS

A systematic search of PubMed, EMBASE, Cochrane, and Web of Science was performed from inception to January 2025 for studies comparing long term or maintenance treatment with STC for EoE compared to placebo. We included studies that investigated patients who underwent successful induction therapy. Pooled data was analyzed for histologic recurrence, symptom recurrence, need for repeat esophageal dilation, use of concomitant PPI, and candida infection rates. A random effects model was used, and the data was presented using odds ratios (OR) with 95% confidence intervals (CI).

RESULTS

Three randomized control trials and one observational study were included, involving 303 patients (189 in the STC group, 114 in the placebo-controlled group). Analysis showed that histologic recurrence was significantly lower with STC (OR: 0.04, 95%CI: 0.01-0.28, P < 0.00001, I² = 78%). Overall symptom recurrence was similar between groups (OR: 0.23, 95%CI: 0.02-3.54, P = 0.29, I² = 92%). On sensitivity analysis, symptom recurrence was significantly lower in the STC group (OR: 0.05, 95%CI: 0.02-0.17, P = 0.00001, I² = 39%). Odds of repeat dilation were significantly lower in the STC group (OR: 0.14, 95%CI: 0.02-0.91, P = 0.04, I² = 0%). Candida infection rates were similar between groups (OR: 6.13, 95%CI: 0.85-44.26, P = 0.07, I² = 24%). Proportion of concomitant PPI use was similar between groups (OR: 1.64, 95%CI: 0.83-3.21, P = 0.15, I² = 0%).

CONCLUSION

For patients who successfully achieved remission of EoE with STC induction therapy, maintaining treatment is effective in sustaining histologic remission, while newer regimens may be effective in preventing symptom recurrence compared to placebo. We found no significant difference for oropharyngeal/esophageal candidiasis with STC maintenance therapy. Future studies with longer follow-up periods are needed.

Intravenous ketamine to prevent post-partum depression following cesarean under neuraxial anesthesia: A systematic review and meta-analysis of randomized controlled trials

BACKGROUND

Postpartum depression (PPD) significantly affects well-being and the ability to function normally, making preventive strategies crucial. The role of intravenous ketamine in preventing PPD, especially after cesarean sections under neuraxial anesthesia, remains unclear and controversial.

OBJECTIVES

This systematic review and meta-analysis aimed to assess the efficacy and safety of perioperative intravenous ketamine administration in preventing postpartum depression among women undergoing cesarean section under neuraxial anesthesia.

SEARCH STRATEGY

A comprehensive electronic search was conducted for literature published from 2000 to January 1, 2023, in multiple databases, including PubMed/MEDLINE and the Cochrane Database of Systematic Reviews, using relevant keywords. Language restrictions were not applied.

SELECTION CRITERIA

The included studies were randomized controlled trials (RCTs) that met the following criteria: adult patients (<18 years) undergoing elective cesarean section under neuraxial anesthesia, peripartum intravenous administration of ketamine, placebo as a comparison group, and postpartum depression as the primary outcome.

DATA COLLECTION AND ANALYSIS

Data were extracted on various parameters, including study characteristics, ketamine protocol, control group details, results, and quality assessment scores. Meta-analysis was performed using the RevMan 5.4 statistical package, and outcomes were assessed using odds ratios (ORs) for dichotomous data and mean differences (MD) for continuous data, using a random effects model.

MAIN RESULTS

Ten studies involving 2219 patients (1094 in the ketamine group and 1125 in the control group) were included. The meta-analysis did not show significant differences in the incidence of PPD or EPDS scores between the ketamine and control groups postoperatively. However, ketamine administration resulted in a reduction in postoperative pain scores and total opioid consumption but increased the incidence of headaches.

CONCLUSION

Perioperative intravenous administration of ketamine does not have a prophylactic effect on postpartum depression in patients undergoing cesarean section under neuraxial anesthesia but does reduce postoperative pain and total opioid consumption. The increased incidence of side effects, such as headaches, dizziness, and drowsiness, warrants further investigation. Additional large RCTs are necessary to further explore ketamine's potential prophylactic effect on PPD.

Surgical approaches for inserting hemiarthroplasty of the hip in people with hip fractures

RATIONALE

Hip fractures affect over 10 million people annually worldwide and are expected to increase with an ageing population, contributing significantly to morbidity, mortality, and healthcare costs. Hemiarthroplasty, a common treatment for displaced femoral neck fractures, accounts for more than half of hip fracture surgeries in older adults. However, the optimal surgical approach - anterior, lateral, or posterior - remains uncertain, with decisions often based on surgeon preference or institutional protocols.

OBJECTIVES

To assess the effects of different surgical approaches for hemiarthroplasty in the treatment of hip fractures.

SEARCH METHODS

We searched CENTRAL, MEDLINE, Embase, and six other databases in November 2024. We also searched two trials registries, nine different conference proceedings, reference lists of included studies, and systematic reviews published within the last five years.

ELIGIBILITY CRITERIA

We included randomised controlled trials (RCTs) and quasi-RCTs in adults with hip fractures comparing different surgical approaches for hemiarthroplasty. We excluded studies of participants with high-energy hip fractures, fractures not associated with osteoporosis, or studies comparing hemiarthroplasty with total hip arthroplasty (THA).

OUTCOMES

We were interested in a primary core outcome set: activities of daily living (ADL), health-related quality-of-life (HRQoL), mobility or functional status, mortality, and pain. Our secondary outcomes were complications, operative details and postoperative care outcomes.

RISK OF BIAS

We used the Cochrane RoB 1 tool to assess risk of bias.

SYNTHESIS METHODS

We performed meta-analyses using RevMan with a generic inverse-variance approach and random-effects models to calculate risk ratios (RRs), mean differences (MDs) or standardised mean differences (SMDs) with 95% confidence intervals (CIs). We used GRADE to determine the certainty of evidence.

INCLUDED STUDIES

We included 27 studies (23 RCTs, three quasi-RCTs, and one combined RCT/quasi-RCT) with a total of 3369 participants. The studies were conducted in Europe and Asia and published between 1981 and 2024. All studies but one focused on intracapsular fractures. The 'typical' included participant was a geriatric woman with an osteoporotic hip fracture treated with hip hemiarthroplasty who was ambulatory prior to injury and had a varying level of cognitive impairment at baseline.

SYNTHESIS OF RESULTS

All but three studies were at high risk of detection bias and had unclear/high risk of bias in at least one domain. We downgraded many outcomes for imprecision, and for risk of bias where sensitivity analysis indicated the estimate was influenced in size or direction by studies with limitations. Anterior versus posterior approaches (7 studies, 455 participants) There was no evidence of a difference in ADL (MD 0.08, 95% CI -0.55 to 0.71; 1 study, 89 participants), mortality (RR 1.0, 95% CI 0.41 to 2.44; 3 studies, 242 participants), or pain (SMD -0.12, 95% CI -0.42 to 0.18; 2 studies, 171 participants) at three-month follow-up, but evidence was of very low-certainty. We found low-certainty evidence of improved early ability to ambulate independently with anterior approach hemiarthroplasty (RR 1.64, 95% CI 1.15 to 2.34; 2 studies, 161 participants). However, no evidence of a difference in measured functional status was shown at three-month follow-up (SMD 0.06, 95% -0.25 to 0.37; 3 studies, 158 participants). No studies reported on early HRQoL. Anterior versus lateral approaches (6 studies, 641 participants) We found no evidence of a difference in ADL (MD 3.08, 95% CI -14.95 to 21.1; 2 studies, 140 participants), or pain (MD -0.29, 95% CI -0.92 to 0.33; 4 studies, 282 participants) at three-month follow-up, but the evidence is very uncertain. There was low-certainty evidence of improved functional status with anterior approach hemiarthroplasty (MD 1.17, 95% CI 0.03 to 2.30; 2 studies, 142 participants). However, this did not reach a clinically important difference. We found that Trendelenburg gait may be reduced slightly with anterior approach hemiarthroplasty at three-month follow-up (RR 0.13, 95% CI 0.04 to 0.40; 1 study, 94 participants). We are unsure of the effect on early HRQoL as no studies reported the outcome, or for early mortality as no events were reported, resulting in a non-estimable effect size. Lateral versus posterior approaches (11 studies, 1840 participants) There was no evidence of a difference in early ADL (MD 0.05, 95% CI -0.33 to 0.43; 1 study, 297 participants), HRQoL (MD -0.03, 95% CI -0.09 to 0.03; 2 studies, 529 participants), functional status (SMD 0.09, 95% CI -0.36 to 0.55; 5 studies, 494 participants), or pain (SMD -0.07, 95% CI -0.41 to 0.27; 6 studies, 752 participants), but evidence was very low-certainty. We found low-certainty evidence of little to no difference between lateral and posterior approaches in mortality (RR 0.88, 95% CI 0.56 to 1.39; 4 studies, 1417 participants).

AUTHORS' CONCLUSIONS

For people undergoing hemiarthroplasty for intracapsular hip fracture, the evidence is very uncertain regarding the effect of surgical approach on activities of daily living and pain within four months. There is little to no evidence of a difference in health-related quality of life, functional status, or mortality between approaches. There is currently insufficient evidence to determine whether anterior, lateral, or posterior approaches are a more appropriate option for hemiarthroplasty for hip fracture with respect to these outcomes. Further research is needed to improve the certainty of evidence, requiring better-powered trials, adherence to reporting standards, prospective trial registration, involvement of experienced surgeons, and blinded outcome assessment to reduce bias. Ensuring the inclusion of the core outcome set for hip fractures and follow-up of at least four months in all RCTs remains essential.

FUNDING

This Cochrane review had no dedicated funding.

REGISTRATION

Registration: Prospero CRD42024498914 Previous version available at: https://doi.org/10.1002/14651858.CD001707.

Oncologic and renal function outcomes of segmental ureterectomy vs. radical nephroureterectomy in upper tract urothelial carcinoma: A systematic review and meta-analysis

Radical nephroureterectomy (RNU) remains the standard of care for patients with upper tract urothelial carcinoma (UTUC). Segmental ureterectomy (SU) has gained traction, given its benefit of preserving renal function without compromising oncologic control, particularly in low-risk disease. However, concerns persist regarding its oncological safety. We aimed to evaluate the oncologic and renal function outcomes in patients who underwent SU and RNU for UTUC. In August 2024, we systematically searched PubMed, Embase, Medline, and Cochrane databases to identify studies comparing oncologic outcomes and renal function preservation in patients who underwent SU and RNU for UTUC. Primary outcomes were cancer-specific survival (CSS), estimated glomerular filtration rate (eGFR) changes, and postoperative eGFR. Secondary outcomes included overall survival (OS), recurrence-free survival (RFS), and metastasis-free survival (MFS). Twenty-nine studies totaling 33,241 patients were included. No significant difference in 5-year CSS was observed between SU and RNU (HR 1.04, [95% confidence interval 0.93. 1.15], P = .49). A statistically significant higher 1-year postoperative eGFR (MD 17, [7.33, 26.67], P = .0006) and less pronounced eGFR change (MD 0.70, [0.24, 1.16], P = .003) were observed in the SU group. Additionally, the 5-year OS, RFS, and MFS were comparable between the groups. SU yielded comparable oncological outcomes to RNU concerning 5-year CSS, OS, RFS, and MFS while providing a higher postoperative eGFR and lower eGFR change at 1-year follow-up. SU might represent a viable treatment modality for UTUC in low-risk and carefully selected high-risk patients, although high-quality prospective trials implementing standardized outcome reporting are needed to draw definitive conclusions.

The Efficacy of Intravenous Analgesia and Various Nerve Blocks for Pain Management in Elderly Patients With Hip Fractures: A Meta-Analysis

Pain management in elderly patients with hip fractures has received more and more attention, which is crucial for promoting recovery and reducing complications. At present, there are various and controversial analgesic methods for this population. This meta-analysis evaluated the analgesic effects and side effects of intravenous analgesia compared to different nerve block techniques, including femoral nerve block, fascia iliaca block or pericapsular nerve group block, in this patient group. The study was conducted following the PRISMA 2020 guidelines. A search was performed in October 2024 across PubMed, Web of Science, Cochrane Library, and Embase. Pain scores at different time points, supplemental analgesic morphine consumption, and adverse reactions were compared between intravenous analgesia and nerve blocks. Data were collected from 12 studies and 1157 elderly patients using intravenous analgesia and nerve block after hip fracture, with no differences in sample size, mean age, or percentage of females between the two groups at baseline. Compared to intravenous analgesia, nerve blocks showed significant advantages in the pain score of 2 h after block (SMD-0.80; 95% CI: -1.23 to -0.38; I2 = 90%) and the supplemental analgesic morphine consumption (SMD = -0.46; 95% CI: -0.73 to -0.19; I2 = 59%). The incidence of adverse reactions and the pain scores at various time points also demonstrated significant differences between the two groups. The application of nerve blocks in elderly patients with hip fractures demonstrates significant clinical advantages, particularly in postoperative pain management, decreasing opioid use, and reducing postoperative complications.

Deep brain stimulation for epilepsy: A systematic review and meta-analysis of randomized and non-randomized studies of thalamic targeting

INTRODUCTION

Deep Brain Stimulation (DBS) of the thalamus for drug-resistant epilepsy (DRE) is an emerging treatment modality. This systematic review and meta-analysis sought to evaluate the efficacy of stimulating different targets within the thalamus.

METHODS

A systematic search of four databases was conducted. Rates for overall seizure reduction (SR), responder rate (RR ≥50 % SR), and seizure freedom (SF) were evaluated at a minimum time point of 12 months post-stimulation commencement in the anterior (ANT) and centro-median (CMN) thalamic nuclei. Subgroup analyses for a minimum 24 months follow up, sensitivity analyses, and funnel plots to assess for publication bias were also performed. Risk of bias was assessed using the ROBINS-I tool.

RESULTS

Fourty-nine articles met the inclusion criteria. The mean seizure reduction (SR) across 21 studies was 62.31 % (95 % CI: 55.99-68.62, p < 0.01). Specifically, SR was 64.28 % for ANT (95 % CI: 57.55-71.01, p < 0.01) and 69.11 % for CMN (95 % CI: 58.14-80.09, p < 0.01). Meta-analyses of 41 ANT studies and 12 CMN studies reported a response rate (RR) of 61.51 % (95 % CI: 54.11-68.9, p < 0.01) and 69.09 % (95 % CI: 54.01-84.16, p < 0.01), respectively. Overall seizure freedom (SF) was 3.57 % % for ANT (95 % CI: 1.86-5.28, p = 0.45) and 1.32 % for CMN(95 % CI: 0-4.45, p = 0.81). For ANT, RR was 67.63 % (95 % CI: 61.04-74.23) for follow-up periods longer than 24 months, and 44.05 % (95 % CI: 26.73-61.38) for periods shorter than 24 months. The SF rate for ANT was 3 % (95 % CI: 1-4 %) for follow-up under 12 months. For CMN, RR was 70 % (95 % CI: 53-87 %) for periods over 24 months, and 68 % (95 % CI: 31-100 %) for periods under 24 months. The SF rate for CMN was 1 % (95 % CI: 0-4 %) for periods under 12 months. There was no strong evidence of publication bias based on funnel plot analysis, and results were consistent across sensitivity analyses. Insufficient data precluded meta-analysis for other nuclei.

CONCLUSION

These findings demonstrate efficacy of ANT and CMN DBS for patients with DRE, defined by responder rate and seizure reduction. Further research is required to optimize patient selection, predict individual response, and assess non-seizure related outcomes.

Effect of del Nido Cardioplegia on Isolated Coronary Artery Bypass Grafting: A Study-level Meta-analysis

The purpose of this study was to evaluate the effect of del Nido cardioplegia versus conventional cardioplegic solutions on early outcomes of isolated coronary artery bypass grafting (CABG). PubMed, Scopus, and the Cochrane Central Register of Controlled Trials were searched through July 2024 to conduct a meta-analysis for a comparison between del Nido and other cardioplegic solutions in isolated CABG. Major end points of the study included operative mortality and morbidities. A random effects model was used to estimate the pooled effect size. For subgroup analyses, meta-analyses were conducted for outcomes derived from either randomized controlled-trials, propensity score analysis, or multivariable analysis. Twenty-four studies met our eligibility criteria, including 4 randomized controlled trials and 5 propensity score-matched studies with a total of 34,737 patients. Operative mortality was not significantly associated with cardioplegic solutions (del Nido vs other solutions; p = 0.262). The incidence of postoperative stroke, reoperation, deep wound infection, and atrial fibrillation was also comparable between the 2 groups. The incidence of postoperative myocardial infarction and renal failure was significantly lower in the del Nido group with a pooled odds ratio of 0.43 (95% confidence interval, 0.24-0.77) and 0.61 (95% confidence interval, 0.45-0.81), respectively. Subgroup analyses also demonstrated these significant differences. In patients undergoing isolated CABG, del Nido cardioplegia provides comparable mortality compared with other cardioplegic solutions. Del Nido solution was significantly protective against myocardial infarction and renal failure.

Comparison of 11 Formulas and Breastfeeding for Atopic Dermatitis and Growth in Pediatric Cow's Milk Protein Allergy: A Systematic Review and Network Meta-Analysis of 23 Randomized Controlled Trials

OBJECTIVE

This study aimed to evaluate the effectiveness of various formulas and the ability of breastfeeding with the exclusion of cow milk protein to reduce the Scoring Atopic Dermatitis (SCORAD) index and promote growth in infants with cow milk protein allergy.

METHODS

We conducted a systematic search of PubMed, Embase, Web of Science, the Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, China National Knowledge Infrastructure, WanFang Data, Weipu, and the China Biomedical Literature Database. The search period ranged from the inception of each database to December 2023 (with an update until January 15, 2025). We included randomized controlled trials (RCTs) comparing formulas and breastfeeding for cow's milk protein allergy in infants. Two independent reviewers extracted data via standardized methods and assessed the risk of bias via the revised Cochrane risk-of-bias 2.0 tool. We performed a network meta-analysis (NMA) via a Bayesian fixed-effects model in RStudio and assessed the certainty of the evidence via the Confidence in Network Meta-Analysis (CINeMA) online application. The protocol for this NMA was preregistered in PROSPERO (No. CRD42024504707).

RESULTS

This analysis included 23 RCTs involving 1997 children and assessed 12 interventions. Compared with the regular formula, the pectin-thickened amino acid formula (TAAF) might reduce the SCORAD index (-12.49, 95% confidence interval [CI] -20.38 to -4.48, low certainty). At ≤6 months of follow-up, compared with rice-hydrolyzed formula (RHF), breastfeeding might improve the length-for-age Z score (LAZ) (0.47, 95% CI 0.13-0.81, moderate certainty), and breastfeeding (0.39, 95% CI 0.02-0.77, low certainty) and extensively hydrolyzed formula (EHF) with probiotics (0.38, 95% CI 0.00-0.77, low certainty) might respectively improve the weight-for-age Z score (WAZ) and weight-for-length Z score (WLZ). At the 12-month follow-up, EHF might improve the LAZ (0.41, 95% CI 0.11-0.71, low certainty) and WLZ (0.37, 95% CI 0.18-0.56, low certainty) compared with RHF, whereas the amino acid formula (AAF) may improve the WAZ (0.33, 95% CI 0.02-0.63, low certainty).

CONCLUSIONS

Low-certainty evidence suggested that TAAF might reduce the SCORAD index. Moderate or low certainty evidence indicated that, at ≤6 months of follow-up, breastfeeding might improve the LAZ and WAZ, whereas EHF with probiotics might improve the WLZ. At the 12-month follow-up, EHF might improve the LAZ and WLZ, whereas AAF might improve the WAZ. However, further high-quality studies would be needed to confirm these findings and assess their safety and cost-effectiveness.

Spinal cord involvement in primary central nervous system vasculitis. A systematic review of clinical, neuroradiological and pathological findings

INTRODUCTION

Primary Angiitis of Central Nervous System (PACNS) is a rare disease featured by transmural inflammation in vessels pertaining to brain, leptomeninges and spinal cord. It is a rare disease and the involvement of the spinal cord represents a rarer and not yet completely investigated subtype.

METHODS

We performed a systematic search of the available literature on Pubmed and Embase, adding backward and forward citations, in order to retrieve the reported cases of PACNS i9nvolvimeng the spinal cord without time limitations. The main aim is to retrieve information about clinical and demographic features, pathological and neuroradiological findings on brain and spinal cord, and, finally, treatment and outcome.  RESULTS: The search provided 33 papers (mainly individual case reports) and 38 patients, with a large age frame (from 12 to 70 years of age), mainly adults. Among these ones 36/38 received a pathological diagnosis and granulomatous pattern was the main reported one. The description of spinal cord involvement in MRI is variable form extensive tumefactive lesions to spinal roots prominent involvement. The mortality is high (29% at the end of the individual follow-up).   DISCUSSION: As in non-spinal involvement, the main limitation of the retrieved cases is the inhomogeneity of the diagnostic and therapeutic pathway with underusing and underreporting of neuroradiolgoical techniques relevant for the diagnosis according with the available diagnostic criteria. Spinal cord involvement confirms its rarity, but it has been associated to a high disability and mortality and the diagnosis of PACNS has therapeutic consequences.  CONCLUSIONS: Spinal cord involvement is present in a minority of PACNS cases with a variety of neuroradiological and pathological findings. The standardization of the diagnostic pathway could help to improve the quality of information in prospective studies.

Impact of perioperative dexmedetomidine on postoperative delirium in adult undergoing cardiac surgery: A comprehensive bibliometrix and meta-analysis

This bibliometrix and meta-analysis aimed to evaluate the efficacy of perioperative dexmedetomidine (DEX) on postoperative delirium (POD) in adult patients undergoing cardiac surgery. A comprehensive search of electronic databases identified 21 randomized controlled trials involving 5210 patients. The primary outcome was the incidence of POD from the first day to seven days post-surgery. The meta-analysis revealed that DEX significantly reduced POD incidence compared to various controls (RR 0.70; 95 % CI 0.54-0.89; P = 0.004). Subgroup analyses showed that DEX was particularly effective when compared to propofol (RR 0.48; 95 % CI 0.30-0.78; P = 0.003). However, no significant differences were observed in the duration of anesthesia, surgery, or ICU/hospital stay. Notably, DEX was associated with a higher incidence of hypotension (RR 1.90; 95 % CI 1.16-3.10; P = 0.01). The study highlights the potential neuroprotective benefits of DEX but underscores the need for careful monitoring of hemodynamic stability. Future research should focus on optimizing DEX dosing protocols and exploring its broader impact on postoperative recovery and patient outcomes.

Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on hemoglobin, B-type natriuretic peptide, and renal function in anemic heart failure patients: A systematic review and meta-analysis

Background

Anemia is a common comorbidity in heart failure (HF) patients, often leading to worsened outcomes. Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors represent a novel approach for anemia management, yet their efficacy and safety in HF patients remain unclear. We aimed to conduct a systematic review and meta-analysis of studies on the effects of HIF-PH inhibitors on hemoglobin, N-terminal prohormone of brain natriuretic peptide (NT-proBNP), or estimated glomerular filtration rate (eGFR) in HF patients with chronic kidney disease (CKD).

Methods and Results

The search of electronic databases identified four studies including 98 patients. Among the included studies, two were conducted prospectively, while two were retrospective in design. No studies were identified that compared HIF-PH inhibitors with erythropoiesis-stimulating agents or placebo. In cases of significant heterogeneity (I2 > 50 %), data were pooled using a random-effects model; otherwise, a fixed-effects model was used. In pooled analyses, hemoglobin levels increased at one (weighted mean difference [WMD]: 0.697 [0.473, 0.920] g/dL; Pfix < 0.001; I2 = 24 %) and three months (WMD: 0.760 [0.443, 1.076] g/dL; Pfix < 0.001; I2 = 31 %) after the use of HIF-PH inhibitors. NT-proBNP levels showed a modest decrease at one month but no significant changes at three months. eGFR remained unchanged, and no severe adverse events were reported.

Conclusion

This meta-analysis suggests that HIF-PH inhibitors effectively improve anemia in HF patients with CKD without notable changes in renal or HF-related biomarkers. However, the small number of included studies and the absence of a comparator group underscore the need for cautious interpretation of the findings.

Estimation of the pooled mean blood lead levels of Indian children: Evidence from systematic review and meta-analysis

A recent systematic review reported very high pooled estimates of blood lead levels (BLLs) for Indian children. Current study aimed at systematically pooling the BLLs of Indian children (aged ≤ 14 years). Further, explore the time trend of BLLs with respect to implementing the ban on the use of Pb-petrol (i.e.2000) and a decade later (2010). Observational studies documenting the BLL in Indian children (aged ≤ 14 years) from PubMed-Medline, Scopus, and Embase digital databases from inception to August 2024 were systematically reviewed. Detailed protocol is available at PROSPERO (ID: CRD42022382835). Pooled mean BLL was estimated using the random-effects model and conventional-I 2 statistics to assess the heterogeneity, while the Newcastle Ottawa Scale for bias assessment. Sub-group, sensitivity, and meta-regression analyses were performed where data permitted. Observations from 65 reports (51 original studies) revealed pooled BLL of 10.4 (95 % CI: 9.55-11.2) µg/dL with a trend of gradual reduction during the last 3 decades. Subgroup analysis revealed the high risk (with known Pb exposure) children had BLL of 14.3 (12.3-16.2) µg/dL, while that of the low risk (no known Pb exposure) is 8.71 (7.71-9.71) µg/dL. Only the low risk group exhibited a time trend of a gradual reduction in BLL. Notably, the review observed high heterogeneity. A progressive decline in Pb burden with respect to the national ban on leaded petrol was observed. However, present observations emphasize remedial actions toward non-occupational Pb exposure particularly among high risk Pb group, such as periodic BLL surveys.

Effects of walnut consumption on biomarkers of oxidative stress: A systematic review and meta-analysis of randomized controlled trials

Oxidative stress is caused by an imbalance between accumulation and production of oxygen reactive species (ROS) in tissues and cells and play a key role in many diseases. This systematic review and meta-analysis of randomized controlled trials (RCTs) was performed to analyze the effects of walnut consumption on biomarkers of oxidative stress. Databases including PubMed, Scopus, Embase and Web of science were searched until November 30th, 2024. Data were subjected to meta-analysis using a random effects model to examine the effect sizes of the pooled results. Four studies were identified eligible to be included in current meta-analysis. Walnut consumption resulted in a significant increase in catalase activity (CAT) (WMD: 42.20; 95 % CI: 34.28, 50.11). Walnut consumption did not affect other biomarkers of oxidative stress such as lipid peroxidation (LPO), reduced glutathione (GSH), oxidized glutathione (GSSG) and oxygen radical absorbance capacity (ORAC). Overall, this meta-analysis demonstrated walnut consumption increase CAT, but did not affect other biomarkers of oxidative stress. This suggests that walnut may have played an indirect and mild role in health. However, due to the limited number of studies, further investigations is suggested in this regard.

Efficacy of supervised exercise on sleep of women who survived breast cancer: a systematic review with meta-analysis

PURPOSE

To analyze the efficacy of supervised exercise (SE) compared with control protocols on sleep parameters of women who survived breast cancer.

METHODS

This systematic review with meta-analysis searched studies using the following electronic databases: PubMed, Scopus, Physiotherapy Evidence Database (PEDro), Cochrane Library, and EMBASE. The PEDro scale assessed the bias risk, and the study protocol was registered in the PROSPERO (no. CRD42023420894).

RESULTS

Of 3,566 identified studies, 13 randomized clinical trials involving 847 women diagnosed with breast cancer were included. Interventions consisted of SE in an outpatient setting (62%) or combined protocols with supervised and home exercises. Most interventions (85%) used multicomponent protocols with aerobic and resistance exercises. Usual care and health education were the most reported controls. SE decreased the sleep disturbance score (- 31.61 [95% confidence interval =  - 39.40 to - 23.83]) of the European Organisation for Research and Treatment of Cancer quality of life questionnaire and daytime dysfunction score (- 0.41 [95% confidence interval =  - 0.73 to - 0.09]) of the Pittsburgh Sleep Quality Index (PSQI). Also, SE presented a tendency to improve the self-reported sleep quality score of the PSQI (p = 0.06).

CONCLUSION

SE increased the subjective sleep quality and immobility time and decreased sleep disturbance and daytime dysfunction symptoms in women who survived breast cancer. Most SE protocols were multicomponent, with aerobic and resistance exercises ranging from moderate to high intensity.

IMPLICATIONS FOR CANCER SURVIVORS

Supervised exercise may improve sleep quality and reduce symptoms of sleep disorders, contributing to survival outcomes.

Head-to-head comparison of DaVinci and Hugo™ RAS robotic platforms for robot-assisted radical prostatectomy: a systematic review and meta-analysis of comparative studies

BACKGROUND

We conducted a systematic review and meta-analysis of comparative studies to analyze intra- and postoperative outcomes of robot-assisted radical prostatectomy (RARP) using either DaVinci (DV-RARP) or Hugo™RAS (H-RARP) platforms.

METHODS

The study was registered in PROSPERO (CRD42024562326) and followed PRISMA guidelines. Literature search was conducted in June 2024 using academic databases, focusing on articles from 2021 to 2024. Research question focused on men with PCa (P) undergoing H-RARP (I) versus DV-RARP (C) to evaluate surgical, pathology, and functional outcomes (O), across comparative studies. Continuous variables were summarized using mean difference (MD) and categorical variables using odds ratio with 95% confidence intervals (CI). Heterogeneity was assessed using Cochran's Q test and I2 statistics. Publication bias was evaluated with Egger's and Begg's tests. Statistical analysis was performed with Stata®17.0, with significance set at p < 0.05. Risk of bias was assessed using the ROBINS-I tool. Methodological quality was evaluated with AMSTAR 2.

RESULTS

Eight studies (three prospective, five retrospective) with 1114 patients (454 H-RARP vs. 660 DV-RARP) were included. Baseline characteristics were comparable between groups. No significant differences were found in overall operative time, console time, blood loss, nerve-sparing, or lymphadenectomy. Docking time was significantly longer for Hugo™RAS (MD:6 min,95% CI 4.2;7.8). Postoperative outcomes, including complications, length of stay, and catheterization time, were similar. Pathological outcomes showed no significant differences in positive surgical margins or staging, but lower node yield was observed with H-RARP (MD:-2,95% CI -3.3;-0.6). Urinary continence recovery was comparable. Risk of bias was moderate to serious.

CONCLUSION

The meta-analysis suggests H-RARP and DV-RARP perform not statistically different across most of analyzed outcomes, except for docking time and lymph-node yield. The longer docking time associated with the Hugo™RAS suggests demanding setup but does not translate into significantly longer operative time. Although statistically significant, the observed difference in lymph-node yield might be clinically negligible.

Telomere length and telomerase activity in men and non-pregnant women with and without metabolic syndrome: a systematic review and bootstrapped meta-analysis

Purpose

We performed a systematic review and meta-analysis to examine the associations between telomere length and telomerase activity in subjects with and without metabolic syndrome (MetS).

Methods

The meta-analysis protocol was registered in the PROSPERO database. The PubMed, Embase, Cochrane Library, and LILACS databases were searched for studies reporting telomere length or telomerase activity in adult men and non-pregnant women with and without MetS. The risk of bias was assessed with the Newcastle-Ottawa Scale. Random effects and inverse variance methods were used to meta-analyze associations. We conducted a bootstrapped analysis to test the accuracy of clinical results.

Results

Five studies reported telomere length and two studies telomerase activity. There was no significant difference in telomere length (standardized mean difference [SMD]: 0.10, 95% confidence interval [CI]: -0.07, 0.28, I 2: 54%), between subjects of similar age (mean difference: 2.68, 95%CI: -0.04, 5.40 years) with and without the MetS. Subjects with MetS displayed significantly higher body mass index, triglycerides, and blood pressure, and lower HDL-cholesterol values than subjects without the syndrome. A bootstrapping mediation analysis of telomere length confirmed the clinical results. There was no significant difference in telomerase activity (SMD: 1.19, 95% CI -0.17, 2.55, I 2: 93%) between subjects with and without the MetS.

Conclusion

There were no significant differences of telomere length and telomerase activity in patients with MetS and subjects of similar age without the syndrome.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40200-024-01513-4.

Efficacy and safety of iGlarLixi versus insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials

OBJECTIVE

This meta-analysis aimed to compare the efficacy and safety of iGlarLixi with those of insulin glargine for treating type 2 diabetes (T2D).

METHODS

A systematic search of PubMed, the Cochrane Library, and EMBASE was conducted to identify randomized controlled trials (RCTs) that compared the use of iGlarLixi with the use of insulin glargine in patients with T2D. The meta-analysis protocol was registered at PROSPERO. The primary outcomes of interest were changes in hemoglobin A1c (HbA1c) and body weight. Risk ratios and mean differences with 95% confidence intervals were calculated using random-effects models.

RESULTS

We included 7 RCTs comprising 2229 men and 1926 women, of whom 2075 (49.94%) were randomized to iGlarLixi. Compared with insulin glargine, iGlarLixi decreased HbA1c (MD: -0.50%; 95% CI: -0.65% to -0.35%; p < 0.00001) and body weight (MD: -1.17 kg; 95% CI: -1.36 kg to -0.98 kg; p < 0.00001) and self-measured plasma glucose (MD: -0.97 mmol/L; 95% CI: -1.27 mmol/L to -0.68 mmol/L; p < 0.00001) and increased the percentage of patients achieving HbA1c < 7% (RR: 1.66; 95% CI: 1.31 to 2.11; p < 0.0001), the percentage of patients achieving HbA1c < 6.5% (RR: 2.11; 95% CI: 1.53 to 2.92; p < 0.00001), and HbA1c < 7.0% without weight gain and/or without severe or blood glucose-confirmed hypoglycemic episodes (RR: 2.18; 95% CI: 1.76 to 2.69; p < 0.00001). However, a higher incidence of gastrointestinal adverse events (RR: 2.02; 95% CI: 1.61 to 2.54; p < 0.00001) and adverse events (RR: 1.08; 95% CI: 1.02 to 1.14; p = 0.008) was associated with iGlarLixi than with insulin glargine.

CONCLUSIONS

Compared with insulin glargine, iGlarLixi is superior in reducing blood glucose levels and facilitating weight loss. Nevertheless, its administration is also linked to a heightened occurrence of gastrointestinal and adverse events.

Patient-Reported Outcome Measures Show No Relevant Change Between 1-Year and 2-Year Follow-Up After Treatment for Anterior Shoulder Instability: A Systematic Review

PURPOSE

To compare patient-reported outcome measures (PROMs) at 1-year and 2-year follow-up after treatment for anterior shoulder instability.

METHODS

Randomized controlled trials and prospective studies that evaluated and reported PROMs after a capsulolabral repair (with or without remplissage), bone augmentation, or nonoperative treatment to treat anterior shoulder instability at both 1-year and 2-year follow-up were included. PROMs were compared between 1-year and 2-year follow-up; forest plots with mean difference were created to compare baseline, 1-year, and 2-year follow-up; and scatterplots were created to visualize clinical improvement over time.

RESULTS

Fourteen studies, comprising 923 patients, with levels of evidence Level I and II were included. Nine PROMs, of which predominantly were the Western Ontario Shoulder Instability Index (WOSI; 11 studies; 79%), were evaluated. Minimal to no statistically significant change in WOSI, Oxford Shoulder Instability Score, American Shoulder and Elbow Surgeons (ASES), Subjective Shoulder Value, Simple Shoulder Test, Disabilities of Arm, Shoulder, and Hand (DASH), Quick DASH, Single Assessment Numeric Evaluation, or visual analog scale was observed between 1-year and 2-year follow-up. Pooling of the WOSI, Oxford Shoulder Instability Score, ASES, and Single Assessment Numeric Evaluation demonstrated improvement from baseline to 1-year follow-up and minimal to no change between 1-year and 2-year follow-up. Scatterplots of the WOSI and ASES demonstrated the most improvement within 6 months and no clear improvement after 1-year follow-up. Recurrence rates increased with time but varied between studies.

CONCLUSIONS

In contrast to recurrence rates, which have been shown to increase with time, minimal to no statistically significant change was observed for any of the included PROMs between 1-year and 2-year follow-up. This finding raises the question as to whether it is necessary to evaluate PROMs in long-term follow-up of patients after shoulder stabilization treatment.

LEVEL OF EVIDENCE

Level II, systematic review of Level I and II studies.

An updated systematic review and meta-analysis of pomegranate consumption on lipid profile

Pomegranate, rich in bioactive compounds such as polyphenols and flavonoids, has been studied for its potential lipid-modulating effects, yet evidence remains inconsistent. This systematic review and meta-analysis aimed to evaluate the impact of pomegranate consumption on plasma lipid profiles by synthesizing data from randomized controlled trials (RCTs). Following PRISMA guidelines, 37 RCTs (n = 2695 participants) were included after searching Scopus and MEDLINE databases. Studies assessed pomegranate products (juice, extract, seed oil) administered orally for ≥ 7 days, with lipid parameters, including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) as outcomes. Data were pooled using RevMan 5.3 with random-effects models. Results indicated that pomegranate intake significantly increased HDL-C levels (mean difference: 2.50 mg/dL, 95 % CI: 1.00-4.00, p < 0.05), while no significant changes were observed in TC, LDL-C, or TG. Subgroup analyses revealed pronounced HDL-C elevation in non-alcoholic fatty liver disease (NAFLD) patients, health participants and interventions lasting ≥ 8 weeks. Heterogeneity across studies was attributed to variations in intervention duration, dosage forms, and participant characteristics. Publication bias was nonsignificant (Egger's test, p > 0.05). These findings suggest that pomegranate supplementation may improve HDL-C, potentially through modulation of HDL-associated enzymes like paraoxonase. However, further large-scale, long-term RCTs are warranted to confirm these effects and explore synergistic benefits with standard lipid-lowering therapies.

Etomidate versus ketamine for in-hospital rapid sequence intubation: a systematic review and meta-analysis

Rapid sequence intubation (RSI) is a critical procedure in emergency and intensive care settings. Etomidate has been favored for its hemodynamic stability; however, concerns about adrenal insufficiency have prompted interest in ketamine as an alternative induction agent. This systematic review and meta-analysis aimed to compare the effects of etomidate vs ketamine on 30-day survival and other clinical outcomes in critically ill patients undergoing in-hospital RSI. A comprehensive literature search was conducted until 1 November 2024, across PubMed, Embase, Web of Science, Cochrane databases, and clinical trial registries. Eligible studies included randomized controlled trials (RCTs) and controlled clinical trials (CCTs) assessing etomidate vs ketamine for RSI. The primary outcome was 30-day survival. Secondary outcomes encompassed intubation difficulty, post-intubation vasopressor use, cardiovascular collapse, Sequential Organ Failure Assessment score, systemic steroid use, organ support-free days, and adrenal insufficiency. Fourteen studies comprising 23 926 patients (19 288 receiving etomidate; 4638 receiving ketamine) met the inclusion criteria. Pooled analyses of RCTs and CCTs revealed no significant difference in 30-day survival between the two agents [RCTs: odds ratio (OR) = 0.92, 95% confidence interval (CI): 0.68-1.24, P  = 0.58; CCTs: OR = 1.16, 95% CI: 0.92-1.45, P  = 0.58]. Ketamine was associated with a higher requirement for post-intubation vasopressor support (OR = 0.71, 95% CI: 0.53-0.96, P  = 0.03) and an increase in ICU-free days. Etomidate use correlated with a significantly higher incidence of adrenal insufficiency (OR = 2.43, 95% CI: 1.67-3.53, P  < 0.001). No significant differences were observed in intubation difficulty, cardiovascular collapse, or systemic steroid use between the groups. Ketamine and etomidate showed no significant difference in 30-day survival among critically ill patients undergoing RSI. However, etomidate was associated with a higher incidence of adrenal insufficiency, while ketamine required more post-intubation vasopressor support. Provenance and peer review: Not commissioned, externally peer-reviewed.

Vascular endothelial dysfunction in pediatric rheumatic diseases: a systematic review and meta-analysis

OBJECTIVES

Endothelial dysfunction is associated with increased cardiovascular risk in individuals with autoimmune diseases. This systematic review and meta-analysis included studies assessing endothelial function with functional methods in children with rheumatic diseases versus controls.

METHODS

Literature search involved PubMed and Scopus databases (from inception to February 2024) and manual reference screening. Studies assessing endothelial function by all available functional methods were eligible. Study quality was evaluated via Newcastle-Ottawa scale.

RESULTS

Twenty-four studies (880 children with rheumatic diseases, 784 controls) were included in meta-analysis. Pooled analysis showed significantly impaired endothelial function in patients versus controls (SMD: -0.74, 95%CI -1.10 to -0.39) but with high heterogeneity (I2 = 91%, p < 0.001); sensitivity analysis including only high-quality studies confirmed this finding (SMD: -0.83, 95%CI -1.20 to -0.46). In subgroup analyses according to type of rheumatic disease, significantly impaired endothelial function was showed for patients with juvenile idiopathic arthritis (SMD: -1.05, 95%CI -1.84 to -0.25), vasculitis (SMD: -0.74, 95%CI -1.11 to -0.37) and juvenile systemic sclerosis (SMD -2.48, 95%CI -4.34 to -0.61).

CONCLUSIONS

Children with rheumatic diseases show impaired endothelial function. Future studies are needed to elucidate whether endothelial dysfunction is involved in high cardiovascular risk of these patients.

PROSPERO REGISTRATION NUMBER

CRD42023413799.

Robot-assisted partial nephrectomy for localized renal masses in elderly and younger patients: a systematic review and meta-analysis of perioperative outcomes

PURPOSE

Robot-assisted partial nephrectomy (RAPN) is an established treatment modality for localized renal masses (LRMs). Nevertheless, its applicability in aging populations presents unique challenges, with limited existing evidence. This meta-analysis aims to evaluate the safety and feasibility of RAPN for LRMs in elderly patients compared to younger individuals.

METHODS

Databases were searched until August 2024 to identify articles comparing RAPN outcomes in elderly and younger patients. Studies were stratified based on age cutoffs for older individuals. Three primary cutoffs were employed for subgroup analysis: 70-74, 75-79, and ≥ 80 years old. Primary outcomes included the incidence of any grade and major complications (Clavien-Dindo ≥ 3) and trifecta achievement. Odds ratios (OR) and mean differences (MD) were used for statistical comparisons.

RESULTS

Seven studies comprising 5,937 patients were included. A significantly higher incidence of any grade complications was observed in elderly patients (OR 1.38 [95%confidence interval [CI] 1.03, 1.84], p = 0.02). However, there was no difference in major complications (OR 1.32 [95%CI 0.79, 2.18], p = 0.28) or trifecta achievement (OR 1.02 [95%CI 0.83, 1.25], p = 0.84) between elderly and younger patients. Similarly, estimated blood loss, transfusion rates, positive surgical margins, and operative time were comparable between groups. Notably, elderly individuals had a shorter warm ischemia time (MD -1.59 [95%CI -2.40, -0.79], p < 0.001).

CONCLUSIONS

RAPN appears to be a viable treatment option for well-selected elderly patients with LRMs who are candidates for active treatment. While elderly patients experienced higher rates of minor complications, major complications and trifecta achievement were comparable to those of younger patients.

Robotic vs. Laparoscopic Adrenalectomy for Pheochromocytoma-A Systematic Review and Meta-Analysis

Background: The application of robotic adrenalectomy (RA) has been increasing. However, there is still controversy about whether RA is more feasible than laparoscopic adrenalectomy (LA) for pheochromocytoma (PHEO). Methods: We conducted a systematic review of published articles between 2013 and 2025 according to the PRISMA statement and the Cochrane Handbook for systematic reviews of interventions. The search was conducted in MEDLINE (PubMed, Scholar, and Cochrane databases). Results: Overall, seven studies including 879 patients (RA 358; LA 521) were included. RA might have larger tumor size (MD -0.66, 95% CI -1.18 to 0.13; p < 0.00001) but not for BMI patients (MD -0.24, 95% CI -1.44 to 0.96; p < 0.00001). There were no statistically significant differences in intraoperative complication, conversion to open surgery, postoperative complications, transfusion rate, and perioperative hemodynamic outcomes with the exception of a higher lowest systolic blood pressure in the LA group (MD -1.09, 95% CI -2.35 to 0.18; p < 0.00001). Moreover, estimated blood loss (MD 29.52, 95% CI 4.19 to 54.84; p < 0.00001), operative time (MD 3.85, 95% CI -16.11 to 23.80; p < 0.00001), and the length of hospital stay were in favor of RA (MD 0.42, 95% CI 0.09 to 0.74; p < 0.0001). Conclusions: Both LA and RA are safe and feasible approaches for adrenalectomy in the case of pheochromocytoma. RA seems to have better perioperative results, but further prospective randomized control studies are required to draw definitive conclusions.

Time to Disease Control with Dupilumab for Bullous Pemphigoid: A Systematic Review and Meta-analysis

Bullous pemphigoid (BP) is a chronic autoimmune blistering disease primarily affecting the elderly population. While awaiting the results from randomized clinical trials to assess the effect of dupilumab in patients with BP, clinicians have begun to introduce dupilumab into their therapeutic arsenal, with few data supporting their clinical decisions. The objectives were to assess time to disease control, predictors of response, achievement of disease control, disease recurrence, and occurrence of adverse events. Randomized and non-randomized studies of interventions (NRSIs) from Medline and Embase were reviewed. A total of 315 studies were identified and 5 NRSIs (167 participants with moderate-to-severe BP) meeting our inclusion criteria were found. Dupilumab was significantly associated with shorter time to disease control compared with the control group (HR 2.71  [95% CI, 1.85-3.96; I2 = 35%; 127 participants; 4 studies]). The overall strength of the evidence was graded as very low due to serious risk of bias and imprecision of effect measures. There were insufficient data to inform conclusions regarding BP recurrence and adverse events. Evidence was found that dupilumab reduces time to disease control in BP. It was not possible to assess predictors of response using pre-planned meta-regression. Randomized controlled trials are needed to determine dupilumab's place in therapeutic algorithms for BP. PROSPERO number: CRD42024599235.

Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis

BACKGROUND

A significant number of patients encounter weight gain (WG) or inadequate weight loss (IWL) following bariatric surgery for obesity. Recent studies have explored the role of semaglutide in addressing weight management challenges in patients who have inadequate weight loss or weight gain after bariatric surgery. Despite such studies, a systematic review and meta-analysis evaluating the efficacy, safety and tolerability of semaglutide in this specific clinical context remains absent. Therefore, this study was undertaken to address this knowledge gap.

METHODS

Databases were searched for randomized controlled trials (RCTs), case-control, cohort and observational studies involving use of semaglutide in the intervention arm post-bariatric surgery. Outcome was weight loss post-bariatric surgery.

RESULTS

A total of six studies (300 participants) demonstrated significant weight reduction following semaglutide administration after bariatric surgery (WMD: - 15.730, 95% CI: - 22.140, - 9.320, p < 0.001). This effect remained robust in sensitivity analysis.

CONCLUSION

The current data encourages the use of semaglutide for managing WG or IWL post-bariatric surgery.

Left colectomy for diverticular disease: systematic review and meta-analysis comparing robotic and laparoscopic resections

BACKGROUND

Around 50% of people aged 60 years and above are affected by diverticular disease, and 25% of these individuals will require surgical intervention. Our objective is to compare the results of left colonic resection for sigmoid diverticular disease using both robotic and laparoscopic approaches. Our primary aim is to conduct a meta-analysis while investigating the rates of conversion to open surgery, stoma and complications between the two methods.

METHODOLOGY

A systematic review was conducted following the PRISMA guidelines. A meta-analysis was performed using RevMan Version 5.4 software. The random-effect model was employed to pool dichotomous outcomes and estimate risk and odds ratios (OR).

RESULTS

Eight studies were thought to fulfil the eligibility criteria: 1892 patients (49.2%) had robotic surgery, and 1952 patients (50.84%) underwent a laparoscopic approach. There were fewer conversions to open surgery in the robotic group when compared to the laparoscopic group (P < 0.00001), a lower rate of postoperative ileus (P = 0.005), shorter length of stay (mean difference (MD) 0.18 P = 0.003) and fewer morbidities (P = 0.002). There were similar rates of stoma formation (4.7%, P = 1.00), anastomotic leak (2.6%, P = 0.85) and mortality (0.3% vs 0.2%, P = 0.59). The operative time was shorter in the robotic approach, although the difference was not significant (P = 0.47).

CONCLUSION

Robotic surgery is feasible for diverticular disease compared to laparoscopic left colectomy. Our study observed a reduction in the conversion to open rate, reduced morbidity, and less ileus while demonstrating similar rates of stoma formation, anastomotic leak, and mortality. However, more high-quality research needs to be conducted to investigate this further. The study is registered in Prospero (reg # CRD42023440509).

Every minute counts: a network meta-analysis comparing the effect of prophylactic endovascular procedures in abnormal placentation

BACKGROUND

Preventing postpartum haemorrhage remains a high priority worldwide. We aimed to provide all available evidence comparing maternal and neonatal outcomes of different prophylactic endovascular procedures in patients with abnormal placentation.

METHODS

Pubmed, Embase and ClinicalTrials.gov databases were searched from inception to Nov, 2024, using relevant key words. Studies comparing outcomes of women undergoing or not prophylactic endovascular procedures in planned cesarean delivery in patients with antenatally suspected or confirmed PAS, placenta previa or both were included. An arm-based random effect frequentist network meta-analysis was performed. All available maternal and neonatal outcomes were evaluated.

RESULTS

Three randomized controlled trials and 59 observational studies were eligible reporting on 6973 women (42.9% did not undergo any endovascular procedure, 26.7% underwent aortic balloon occlusion, REBOA, 16.6%, internal iliac balloon occlusion, PBO-IIA, 5.8%, common iliac artery occlusion, PBO-CIA, placement, and 7.8% underwent uterine artery embolization, UAE). The pooled network analysis showed that all prophylactic endovascular procedures were associated with reduced perioperative blood loss, with proximal balloon occlusion (REBOA) having the strongest effect (SMD -1.80 L, 95%CI -2.38;-1.21; I2 = 97.2%). Also, peripartum hysterectomy rates were significantly lower in women undergoing prophylactic UAE and REBOA compared to the control group; moreover, patients with placenta previa without any prophylactic endovascular procedure had a 4 to fivefold increased risk of peripartum hysterectomy compared to the REBOA group (I2 = 20.6%). REBOA was associated with a significant decrease in massive transfusion rates (I2 = 0%), surgery-related complications (I2 = 0%), ICU admissions (I2 = 40.3%), and units of red blood cells transfused (I2 = 92.8%), compared to PBO-IIA and control groups. The control group versus women undergoing prophylactic UAE showed a significant increase in total operative time (I2 = 96.5%) and Clavien-Dindo grade IV post-operative complications (I2 = 26%), compared to REBOA. All prophylactic endovascular procedures had a comparable risk ratio in terms of units of platelets transfused, maternal mortality, and use of additional post-operative bilateral uterine artery embolization among the treatment groups. As for neonatal outcomes, no significant differences were detected.

CONCLUSIONS

Although the preponderance of observational studies suggests caution in interpreting the results of this meta-analysis, our findings suggest that prophylactic endovascular interventional procedures, particularly aortic balloon occlusion, may substantially improve clinical outcomes in women with PAS, placenta previa or both.

PROSPERO REGISTRATION NUMBER

CRD4202457398.

Effect of acupressure and acupuncture on sleep quality in cancer patients with insomnia: A systematic review and meta-analysis

INTRODUCTION

Cancer patients frequently experience insomnia, adversely affecting their quality of life. This study aimed to systematically review and analyse the effectiveness and safety of acupressure and acupuncture in improving sleep quality among cancer patients suffering from insomnia, providing evidence for non-pharmacological treatment options.

METHODS

Several digital databases (Scopus, PubMed, Embase, Web of Science, Medline, Cochrane library, PsycINFO, CINAHL complete, and Google Scholar) were examined for English-language records. Inclusion criteria involved randomized controlled trials assessing the impact of acupressure or acupuncture on cancer patients with insomnia. The Cochrane Collaboration's instrument was employed to evaluate the quality of the encompassed studies. For meta-analysis, a model that accounts for variability among studies was favoured, and statistical analysis was conducted using Stata software version 17.

RESULTS

This review analysed 13 randomized controlled trials involving 806 cancer patients. The analysis indicated that sleep quality didn't differ significantly between treatment and control groups. However, sleep efficacy was significantly higher in the treatment group (SMD [95 % CI] = 0.43 [0.21, 0.65]). Additionally, total sleep time showed a significantly higher extent in the treatment group (SMD [95 % CI] = 0.58 [0.24, 0.92]). No significant differences were found for depression or sleep onset latency between groups, while anxiety levels were lower in the treatment group (SMD [95 % CI] = -0.52 [-0.90, -0.15]).

CONCLUSION

The review suggests that acupressure and acupuncture enhance sleep quality in cancer patients suffering from insomnia, showing notable benefits during follow-up, especially among Asian participants.

Adipose- and bone marrow-derived stromal cells reduce pain in patients with knee osteoarthritis but do not substantially improve knee functionality: an updated systematic review and meta-analysis

PURPOSE

To perform a systematic review and meta-analysis of randomized and comparative studies comparing mesenchymal stromal cells other orthobiological injections for patients with knee osteoarthritis.

METHODS

Systematic review of Medline, Embase, Scopus, and Google Scholar, including all level 1-3 from 2014 to 2024. Validated scores (VAS, KOOS, Lysholm, IKDC) were included as outcome measures. Risk of bias was assessed using the Cochrane Collaboration's tools. The GRADE system was used to assess the quality of the body of evidence and the modified Coleman Methodology score was used to assess study quality. Heterogeneity was assessed using χ2 and I2 statistics.

RESULTS

Ten studies were included; all published in English between 2019 and 2023, encompassing a total of 563 cases (281 treated with MSCs and 282 with other biologics). Two studies had a high risk of bias, one had some bias, and seven had a low risk of bias. Publication bias was detected (Egger's test 3.26447; p = 0.007). The pooled estimates revealed significant differences favoring MSCs for VAS scores at 3, 6, and 12 months. For KOOS pain and symptoms, significant differences were observed at 3 and 6 months.

CONCLUSION

The results of this meta-analysis demonstrated a significant effect of adipose and bone marrow-derived stromal cell injections on pain reduction at all assessed time points, and showed superiority over other non-surgical treatment options. These differences were not reflected in clinical and functional outcomes, indicating that the observed reduction in pain did not correspond to substantial improvements in knee functionality.

Intraepidermal Nerve Fiber Density as an Indicator of Neuropathy Predisposition: A Systematic Review with Meta-Analysis

Background/Objectives: Skin spot biopsy is the gold standard for diagnosing small fiber neuropathy. A systematic approach to intraepidermal nerve fiber density (IENFD) was conducted to estimate its value precisely in healthy and neuropathic subjects, independent of the neuropathy disease. The findings will serve as a guidance model for IENFD as an indicator of neuropathy predisposition. It was also investigated how IENFD was influenced by age, gender, and neuropathy. Methods: A systematic search of PubMed, Web of Science, and ScienceDirect was conducted to identify clinical studies from 1997 to 2022 concerning IENFD in healthy and neuropathic adult populations. Data were retrieved from longitudinal cohort studies, including 5-188 healthy and 6-40 neuropathic patients. Multilevel meta-regression was employed to assess associations between the anatomical region, mean patient age, and male/female ratio with IENFD. This method accounted for correlations between multiple outcomes from the same survey, offering a more nuanced analysis than standard meta-regression. Results: In the healthy population, the estimated (95% CI) IENFD values (fibers/mm) were 21.4 (19.9, 22.9) in the thigh, 17.7 (15.3, 20.1) in the forearm, 12.9 (11.8, 14.0) in the distal leg, 11.3 (6.1, 16.5) in the fingers, and 6.5 (4.4, 8.6) in the toes. The corresponding estimates in the neuropathic population were 17.2 (15.2, 19.2) in the thigh, 6.3 (2.3, 10.2) in the forearm, 5.1 (3.8, 6.4) in the distal leg, and 2.0 (0.0, 5.7) in the toes. In a healthy population, IENFD decreased with aging by 1.35 fibers/mm every 5 years (p < 0.001). Gender dimorphism in IENFD existed, with females showing higher values in the distal leg (13.6-10.5) compared to males (9.3-7.2). Conclusions: The systematic study and meta-analysis integrate evidence of IENFD in skin biopsies. This analysis reconciles findings from various methodologies and populations over two decades. Meta-regression techniques address variability due to biopsy site, fixation protocols, immunohistochemical markers, and demographics. To reduce future study heterogeneity, using the thigh is advisable as it shows the least variability. Additionally, standardizing the biopsy site internationally will ensure comparability. These findings urge further investigation into IENFD changes in neurodegenerative diseases and whether IENFD can be a reliable prognostic marker for neuropathy diagnosis.

ALIF vs. posterior fusion for lumbar degenerative disease: comparable efficacy but elevated risk of severe complications-a systematic review and meta-analysis

BACKGROUND

Over the past years, there has been an upward trend in the total number of spinal fusion procedures worldwide. There are many different strategies to perform the lumbar fusion, each with some advantages. Hospital charges for lumbar spinal surgeries also have increased significantly, with great variation in the costs and recommendations of different surgical procedures. There has also been a trend increase in the rate of the use of interbody fusion implants compared to that of traditional decompression surgery, even though the former is known to incur higher costs. Access through the anterior route gained many followers after studies on sagittal balance, and its indication has also increased worldwide. However, this technique presents different patterns of complications from those observed in traditional posterior approaches.

OBJECTIVES

This study aims to determine the safety and efficacy of surgery in managing patients with symptomatic lumbar degenerative diseases by comparing the effectiveness of posterior and anterior approach techniques to treat this condition on patient-related outcomes. We also aimed to investigate the safety of these surgical interventions by including perioperative complication data.

METHODS

A systematic search of multiple online databases was conducted up to August 2024 to identify randomized controlled trials (RCTs) and other high-quality retrospective studies comparing outcomes of anterior lumbar interbody fusion (ALIF) versus posterior fusion techniques (PLF, PLIF, TLIF) in the treatment of degenerative lumbar diseases. The primary outcomes assessed included the Oswestry Disability Index, Visual Analogue Scale, and overall clinical improvement. Secondary outcomes encompassed complications such as mortality, infections, gastrointestinal complications, deep vein thrombosis (DVT), surgical site infections, and the need for blood transfusions, as well as length of hospital stay and operative duration. Pooled effect estimates were calculated and presented as mean differences (MD) with 95% confidence intervals (CI) at the two-year follow-up.

RESULTS

Regarding VAS and ODI, anterior and posterior approaches were similar in analyzing five RCTs. Including retrospective studies, we also found that the length of hospital stay and duration of surgery were comparable between the two approaches. Anterior approaches had a lower rate of patients requiring blood transfusions OR 0,69[0.60,0,80]. Anterior approaches showed higher rates of mortality (0,21%) OR1,33[1.10,1.62], deep vein thrombosis (0,65%) 1.73 [1.35, 2.20], and gastrointestinal complications (4,9%) OR 2.19 [1.73, 2.78].

CONCLUSION

Clinical outcomes measured by VAS and ODI were comparable between anterior and posterior approaches, demonstrating similar efficacy in treating lumbar degenerative diseases. However, the safety profiles varied significantly. Anterior approaches carried higher rates of severe complications, including mortality, DVT, and gastrointestinal events, while posterior techniques were linked to increased blood transfusion needs. Given the elevated risk of severe complications with ALIF, posterior approaches should be prioritized as the first-line option for lumbar degenerative disease.

Radiosurgery for central nervous system ependymomas: a systematic review and meta-analysis

BACKGROUND

Ependymomas, rare malignant central nervous system (CNS) lesions (2-6% of primary CNS tumors), are typically treated with maximal safe resection followed by fractionated radiation therapy. Stereotactic radiosurgery (SRS) has emerged as an alternative, particularly in recurrent or residual cases. This study evaluates the safety and efficacy of SRS for CNS ependymomas, while also identifying key prognostic factors.

METHOD

A systematic search was conducted to identify studies that evaluated the efficacy and safety of SRS in WHO Grade 2/3 CNS ependymoma patients. Random-effect meta-analysis was employed.

RESULTS

Fourteen studies with 298 patients and 496 lesions were included. Our meta-analysis demonstrated an overall local tumor control (LTC) rate of 72% (95% CI: 65-79%). LTC rates at 1, 3, and 5 years were 83% (95% CI: 76-88%), 72% (95% CI: 64-78%), and 69% (95% CI: 61-76%), respectively. Progression-free survival (PFS) rates at 1, 3, and 5 years were estimated at 67% (95% CI: 50-80%), 56% (95% CI: 48-64%), and 51% (95% CI: 39-63%), respectively. Additionally, the 5-year overall survival (OS) rate was 58% (95% CI: 48-67%). The incidence of adverse radiation events (ARE) was 20% (95% CI: 12-31%). Meta-regression showed older age correlated with improved tumor control (P = 0.02) and lower ARE (P = 0.06) and radionecrosis rates (P < 0.01), while larger tumor volumes (P = 0.03) and anaplastic histology (P = 0.01) were associated with poorer PFS.

CONCLUSIONS

SRS is a reasonably valuable therapeutic option in the multimodal management of WHO Grade 2/3 CNS ependymomas, especially for individuals with inoperable, recurrent, or residual lesions. Key patient and tumor characteristics have been analyzed to determine factors potentially impacting treatment outcomes.

Exploring the Efficacy and Safety of Argatroban as an Adjunct to Antiplatelet Therapy in Ischemic Stroke Patients: A Systematic Review and Meta-analysis

Acute ischemic stroke (AIS) is a major cause of disability and mortality worldwide. While antiplatelet therapy is standard for secondary prevention, many patients still experience early neurological deterioration (END). Argatroban, a direct thrombin inhibitor, can potentially limit thrombus progression and improve AIS's functional outcomes. This meta-analysis assessed the efficacy and safety of argatroban in combination with single (SAPT) or dual antiplatelet therapy (DAPT) compared to antiplatelets alone. Following PRISMA guidelines, a systematic search of PubMed, Scopus, and Web of Science was conducted until January 2025. Randomized controlled trials (RCTs) and cohort studies evaluating argatroban plus antiplatelets versus antiplatelets alone in AIS patients were included. The primary outcome was a 90-day modified Rankin Score (mRS) of 0-2. Secondary outcomes included mRS 0-1 and mRS 3-5 at 90 days, END, and National Institutes of Health Stroke Scale (NIHSS) improvement, stroke recurrence, intracranial hemorrhage (ICH), symptomatic intracranial hemorrhage (sICH), and mortality. We used the mean difference (MD) for continuous variables and odds ratio (OR) for dichotomous ones at 95% confidence intervals (CI) and a P-value of 0.05. A total of 14 studies (four RCTs and 10 cohort studies) were included. Compared to antiplatelets alone, argatroban significantly improved functional outcomes, increasing the incidence of mRS 0-2 (OR = 1.36 [95%CI: 1.05, 1.76, P = 0.02]) and mRS 0-1 (OR = 1.54 [95%CI: 1.08, 2.2, P = 0.02]) while reducing END (OR = 0.42 [95%CI: 0.21, 0.85, P = 0.02]). Argatroban was also associated with greater NIHSS score improvement (MD =  - 0.52 [95%CI: - 0.89, - 0.15, P = 0.005]). No significant differences were observed in mRS 3-5, stroke recurrence, ICH, sICH, or mortality. Subgroup analysis indicated that argatroban combined with DAPT showed the greatest benefits. Argatroban combined with antiplatelet therapy improves functional recovery and reduces END without increasing bleeding risks. These findings support its use, particularly with DAPT, in mild to moderate AIS management. Further large-scale RCTs are needed to optimize dosing strategies and patient selection.

Eat, sleep and console model of care for managing infants with neonatal abstinence syndrome: a meta-analysis of observational studies

IMPORTANCE

Vigilant clinical assessment is the key to preventing complications, including death, in infants at risk of neonatal withdrawal syndrome. The eat, sleep and console (ESC) is proposed as an alternative to usual care with Finnegan's Neonatal Abstinence Scoring System (FNASS), but whether ESC improves infant outcomes is uncertain.

OBJECTIVE

To conduct a meta-analysis and systematic review of outcomes of studies comparing ESC to FNASS.

DATA SOURCES

PubMed, Embase, CINAHL and Cochrane were searched. There was no date restriction.

STUDY SELECTION

Published data from observational studies published in English were included. Randomised controlled trials, reviews and abstracts were excluded. Data was required to be converted to mean and SD to be included.

DATA EXTRACTION AND SYNTHESIS

Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines were used, and data were independently extracted by multiple observers. Data was pooled using a random-effects model.

MAIN OUTCOME AND MEASURES

Length of stay (LOS) in days, number of days medicated and proportion of infants medicated were the primary outcomes assessed. It was hypothesised prior to data collection that ESC would be associated with shorter LOS and a lower proportion of infants medicated, given key differences in infant assessment compared with the FNASS.

RESULTS

12 studies, all from the USA, were published between 2018 and 2024. 10 quality improvement studies and two cohort studies compared ESC (n=1877) with historical controls using FNASS (n=2199). ESC decreased hospitalisation days (MD -4.11 days, 95% CI -6.04 to -2.19 days; p<0.0001; I2=95%; 10 studies; 3703 participants) and the proportion treated with withdrawal medications (OR 0.36, 95% CI 0.22 to 0.60; I2=89%; RD -0.22; 95% CI -0.34 to -0.10; p<0.0001; I2=93%; 12 studies; 4076 participants). One study assessed physical health up to 1 week after discharge (n=1), three assessed weight loss (n=3) and one assessed cost (n=1).

CONCLUSIONS AND RELEVANCE

The majority of evidence for a reduction in hospitalisation and need for withdrawal medication with ESC compared with FNASS is derived from quality improvement and cohort studies with almost no health information beyond 1 week after discharge. High-quality trials incorporating physiological measurements of infant stress and longer-term outcomes are needed.

REVIEW PROSPECTIVE REGISTRATION

CRD42024532169.

Moderate- to Long-Term Effect of Dietary Interventions for Depression and Anxiety : A Systematic Review and Meta-analysis

BACKGROUND

Dietary interventions are a potential alternative treatment of depression and anxiety.

PURPOSE

To evaluate the effects of dietary interventions on depression and anxiety.

DATA SOURCES

PubMed, Cochrane CENTRAL, EMBASE, CINAHL, and PsycINFO searched from inception until 12 December 2024. Trial registries and forward and backward citation analysis done on 3 January 2025.

STUDY SELECTION

Randomized controlled trials (RCTs) evaluated the effect of dietary advice with or without food provision compared with no specific dietary advice or active interventions for 3 months or longer on depression and/or anxiety.

DATA EXTRACTION

Two authors independently screened articles, extracted data, and assessed risk of bias. Primary outcomes included depression and anxiety symptoms at 3 months or longer. Random-effects meta-analyses were done, and the certainty of evidence was assessed.

DATA SYNTHESIS

Twenty-five RCTs were included. Compared with no specific dietary advice, depressive symptoms might be improved in adults with elevated cardiometabolic risk by dietary advice on calorie restriction (standardized mean difference [SMD], -0.23 [95% CI, -0.38 to -0.09]; low certainty). Low-fat diets may also have very small effects on depressive symptoms in adults with elevated cardiometabolic risk (SMD, -0.03 [CI, -0.04 to -0.01]; low certainty). Evidence on other diets, comparing diets with active comparisons, and on anxiety was limited by study limitations and clinical or methodological heterogeneity.

LIMITATION

Limited studies did not allow for adequate exploration of heterogeneity.

CONCLUSION

Calorie restrictions and low-fat diets might reduce depressive symptoms among adults with elevated cardiometabolic risk, but the differences were small and confidence in the findings was low. Evidence on other diets, comparisons to active interventions, and other outcomes is limited.

PRIMARY FUNDING SOURCE

None. (PROSPERO: CRD42023485953).

Exploring the role of melatonin in managing sleep and motor symptoms in Parkinson's disease: a pooled analysis of double-blinded randomized controlled trials

BACKGROUND

Parkinson's disease (PD), a progressive neurodegenerative disorder, often involves sleep disturbances, affecting 88-98% of patients. Melatonin, a sleep-regulating neurohormone, shows the potential to improve sleep quality and non-motor symptoms in PD.

AIM

To evaluate melatonin's efficacy and safety in PD patients with sleep disorders.

METHODS

We systematically searched PubMed, Scopus, Web of Science, and Cochrane till January 2025. The risk of bias in the included studies was evaluated using the Cochrane risk-of-bias tool. Dichotomous outcomes were expressed as risk ratios (RRs) with 95% confidence intervals (CIs), while continuous outcomes were reported as mean differences (MDs) with 95% CIs.

RESULTS

We retrieved 2537 records. Five double-blinded RCTs were finally included. The meta-analysis revealed a significant improvement in sleep quality, as measured by the Pittsburgh Sleep Quality Index (PSQI), in the melatonin group compared to placebo (MD= -1.88, 95% CI: [-3.07, -0.68], P = 0.002). However, no significant differences were observed for the Epworth Sleepiness Scale (MD= -1.04 CI: [-2.81, 0.73], P = 0.25), total sleep time (MD = 14.85 min CI: [-5.45, 35.16], P = 0.15), sleep efficiency, sleep latency, REM sleep latency, frequency of arousals, or REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ; MD = 0.74, P = 0.50). For Parkinson's disease-related outcomes, melatonin significantly improved Non-Motor Symptom Scale (NMSS) scores but showed no significant effects on UPDRS Part III scores or Parkinson's Disease Quality of Life.

CONCLUSION

Melatonin improves subjective sleep quality and non-motor symptoms in PD patients with a favorable safety profile, but effects on objective measures and motor symptoms remain inconclusive.

TRIAL REGISTRY NUMBER

This meta-analysis was registered on PROSPERO.

REGISTRATION NUMBER

CRD42024619496.

Multi-Domain Indoor Dataset for Visual Place Recognition and Anomaly Detection by Mobile Robots

Visual location recognition encompasses place recognition (PR) and anomaly detection (AD). These are crucial tasks for autonomous robots to accurately determine the location and the occupied place. To accelerate research in this area, we introduce a multi-domain dataset for indoor visual place recognition and anomaly detection by mobile robots. The dataset includes 89,550 RGB images captured in nine rooms. The data collection process involved both manual recordings and recordings captured by mobile robots. The images depict a wide range of scenarios, including variations in lighting, robot vision, and human activity. Additionally, we provide an analysis of other available datasets referenced in the literature. This article presents a freely available dataset for research on place recognition and presents an example application in the field of anomaly detection. The baseline methods were thoroughly tested and achieved an 80.18% accuracy in anomaly detection for single images and 80.63%-84.18% for image sequences. The article includes a comprehensive presentation of the characteristics of individual image sequences and the most significant conclusions drawn from the research.

The effects of policosanol supplementation on creatinine: a systematic review and dose-response meta-analysis of randomized controlled trials

OBJECTIVE

Policosanol, a compound generated from sugar cane, consists of alcohols such as octacosanol, hexacosanol, and triacontanol, which possess antioxidant properties. Evaluating the impact of this antioxidant on serum creatinine in clinical settings is essential because of the contradictory findings. This comprehensive review and dose-response meta-analysis attempts to evaluate the impact of policosanol supplementation on creatinine levels.

METHODS

A comprehensive search was performed in bibliographic databases such as Cochrane, PubMed, Google Scholar, Scopus, and Web of Science, covering the period from inception to November 2023. The necessary data was retrieved, and pertinent randomized controlled trials (RCTs) that satisfied the inclusion criteria were included. Weighted mean differences (WMDs) were the reported measure of the pooled effects. To find between-study heterogeneities, the I-squared test was employed.

RESULTS

A total of 2427 participants were involved in the twenty-one RCTs that were included. A meta-analysis showed that policosanol had no significant change in creatinine levels in participants consuming policosanol compared to placebo consumers (WMD = 0.21 µmol/l; 95% CI = - 0.85 to 1.26; P = 0.70). Policosanol consumption for durations ≥ 24 weeks significantly decreased creatinine, according to subgroup studies. There was a non-linear correlation between changes in creatinine levels and the dosage of prescription policosanol (P non_linearity = 0.002). However, the treatment time did not have a significant impact on creatinine levels in a non-linear manner (P non_linearity = 0.24).

CONCLUSION

Policosanol supplementation has no significant effect on creatinine levels.

Efficacy of artemisinin-based combination therapy (ACT) in people living with HIV (PLHIV) diagnosed with uncomplicated Plasmodium falciparum malaria in Africa: a WWARN systematic review

BACKGROUND

Africa bears the highest double burden of HIV and malaria worldwide. In 2023, an estimated 25.9 million people were living with HIV (PLHIV), and 246 million malaria cases were diagnosed in Africa. Malaria patients co-infected with HIV are considered at a higher risk of failing malaria treatment, according to the World Health Organization (WHO) guidelines. This systematic literature review aims to assess the treatment outcomes following artemisinin-based combination therapy (ACT) in PLHIV.

METHODS

The literature search was conducted up to April 2022 in the following databases: MEDLINE, EMBASE, Web of Science, Cochrane Central, WHO Global Index Medicus, Clinicaltrials.gov, and the WorldWide Antimalarial Resistance Network (WWARN) Clinical Trial Library. Studies describing any malaria treatment outcomes or anti-malarial drug exposure in PLHIV treated for uncomplicated Plasmodium falciparum malaria infection were eligible for inclusion.

RESULTS

A total of 26 articles describing 19 studies conducted between 2003 and 2017 in six countries were included in this review; it represented 2850 malaria episodes in PLHIV across various transmission settings. The most studied artemisinin-based combination was artemether-lumefantrine (in 16 studies). PLHIV were treated with various antiretroviral therapy (ART) regimens, namely efavirenz (EFV), nevirapine (NVP), atazanavir-ritonavir (ATVr), lopinavir-ritonavir (LPV/r), and/or on prophylaxis with trimethoprim-sulfamethoxazole (TS), or were untreated (in 3 studies). There was no evidence of an increased risk of recrudescence in PLHIV compared to those without HIV. When treated with artemether-lumefantrine, PLHIV receiving LPV/r had a lower risk of malaria recurrence compared to PLHIV on NVP-based or EFV-based ART, or those without HIV. LPV/r increased lumefantrine exposure and EFV-treated patients had a reduced exposure to both artemether and lumefantrine; NVP reduced artemether exposure only.

CONCLUSIONS

Limited data on ACT outcomes or drug exposure in PLHIV in Africa remains a reality to date, and the effect of antivirals appears inconsistent in the literature. Considering the heterogeneity in study designs, these review's findings support conducting an individual patient data meta-analysis to explore the impact of antiretroviral therapy on anti-malarial treatment.

TRIAL REGISTRATION

The protocol for the original search was published on PROSPERO with registration number CRD42018089860.

Intravenous immunoglobulin versus placebo in recurrent pregnancy loss: A systematic review and meta-analysis of randomized trials

Recurrent pregnancy loss (RPL) affects 1-2 % of fertile couples, with immunological factors increasingly implicated in unexplained cases. Currently, no convincing treatment exists. Intravenous immunoglobulin (IVIg) has been explored as a potential treatment, but results have been inconsistent. This study evaluates whether IVIg affects live birth rates in women with RPL in subsequent pregnancies. We searched PubMed, Embase, and Cochrane libraries for relevant randomized controlled trials up to March 20, 2023, and contacted authors for individual patient data. Trials involving women with two or more consecutive pregnancy losses who received IVIg or placebo before or during the first trimester were included. Primary outcomes were live birth and clinical pregnancy rates, with secondary outcomes including pregnancy loss rate, side effects, adverse events, and perinatal outcomes. Risk of bias and certainty of evidence (GRADE) were evaluated. Ten studies involving 662 women were included. The intention-to-treat analysis showed no significant difference in live birth rates between IVIg and placebo groups (RR: 1.02, 95 % CI: 0.86-1.22, p = 0.78, GRADE: moderate). However, per-protocol analysis indicated an increased live birth rate with IVIg (RR: 1.23, 95 % CI: 1.00-1.50, GRADE: low). Live birth rates after IVIg improved with the number of previous losses, especially in patients with ≥ 6 losses (RR: 5.26 (1.58-17.53)). While IVIg therapy did not show a significant improvement in live birth rates overall, future research should focus on identifying specific patient subgroups, such as those with multiple prior losses, who may benefit most from this treatment.